Skip to main content

Advertisement

SpringerLink
Log in

Update on overactive bladder: Pharmacologic approaches on the horizon

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Limitations exist with regard to the array of available agents for the pharmacologic therapy of overactive bladder, including issues of efficacy and tolerability. It is clear that the ideal agent for this condition has not been identified. However, several new pharmacologic treatments, including some with novel approaches to drug delivery, have emerged in clinical development over the past few years. These agents include a variety of anticholinergics and others. In initial studies, some of the agents appear to compare favorably with existing therapies. Whether these promising results will hold up when subjected to large-scale, well-controlled clinical trials is unclear.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Diokno AC, Lapides J: Oxybutynin: a new drug with analgesic and anticholinergic properties. J Urol 1972, 108:307–309.

    PubMed  CAS  Google Scholar 

  2. Rovner ES, Wein AJ: Modern pharmacotherapy of urge urinary incontinence in the U.S.: tolterodine and oxybutynin. Br J Urol 2000, 86:44–54.

    CAS  Google Scholar 

  3. Wein AJ: Neuromuscular dysfunction of the lower urinary tract and its management. In Campbell’s Urology, edn 8. Edited by Walsh PC, Retik A, Vaughan ED Jr, et al. Philadelphia: WB Saunders; 2002.

    Google Scholar 

  4. Andersson KE, Appell RA, Cardozo L, et al.: Pharmacological treatment of urinary incontinence. In Incontinence. Edited by Abrams P, Khoury S, Wein AJ. Plymouth, UK: Heath Publication Ltd; 1999:447–486.

    Google Scholar 

  5. Hay-Smith J, Herbison P, Ellis G, Moore K: Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2002, 3:CD003781.

    PubMed  Google Scholar 

  6. Yoshimura N, Chancellor MB: Current and future pharmacological treatment for overactive bladder. J Urol 2002, 168:1897–1913. This is a comprehensive review of many of the preclinical and clinical studies of potential pharmacologic therapies for overactive bladder. Included is an interesting discussion of future (theoretical) potential advances, including gene therapy.

    Article  PubMed  CAS  Google Scholar 

  7. Sellers DJ, Chapple CR, Chess-Williams R: Potential therapeutic targets for treatment of the overactive bladder. World J Urol 2001, 19:307–311.

    Article  PubMed  CAS  Google Scholar 

  8. Rovner ES, Wein AJ: Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol 2002, 41:6–14.

    Article  PubMed  CAS  Google Scholar 

  9. Van Kerrebroeck P, Kreder K, Jonas U, et al.: Tolterodine oncedaily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001, 57:414–421.

    Article  PubMed  Google Scholar 

  10. Anderson RU, Mobley D, Blank B, et al.: Once-daily controlled versus immediate-release oxybutynin chloride for urge incontinence. J Urol 1999, 16:1809–1812.

    Google Scholar 

  11. Gupta SK, Sathyan G: Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999, 39:289–296.

    PubMed  CAS  Google Scholar 

  12. Buyse G, Waldeck K, Verpoorten C, et al.: Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 1998, 160:892–896.

    Article  PubMed  CAS  Google Scholar 

  13. Hughes KM, Lang JC, Lazare R, et al.: Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992, 22:859–869.

    PubMed  CAS  Google Scholar 

  14. Waldeck K, Larsson B, Andersson KE: Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997, 157:1093–1097.

    Article  PubMed  CAS  Google Scholar 

  15. Davila GW, Daugherty CA, Sanders SW, et al.: A short-term, multicenter, randomized, double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001, 166:140–145. Represents the initial peer-reviewed publications on the use of transdermal antimuscarinic therapy for overactive bladder.

    Article  PubMed  CAS  Google Scholar 

  16. Dmochowski RR, Davila GW, Zinner NR, et al.: Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002, 168:580–586. Represents the initial peer-reviewed publications on the use of transdermal antimuscarinic therapy for overactive bladder.

    Article  PubMed  CAS  Google Scholar 

  17. Dmochowski R, Davila W, Sanders S: Transdermal oxybutynin and controlled release oral tolterodine in patients with positive treatment effect to anticholinergic therapy for overactive bladder. Neurourol Urodyn 2002, 21:380–381.

    Google Scholar 

  18. Brendler CB, Radebaugh LC, Mohler JL: Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 1989, 141:1350–1352.

    PubMed  CAS  Google Scholar 

  19. O’Flynn KJ, Thomas DG: Intravesical instillation of oxybutynin hydrochloride for detrusor hyper-reflexia. Br J Urol 1993, 723:566–570.

    Article  Google Scholar 

  20. Boone TB, Appell RA, Lopez MA, et al.: Pharmacokinetics evaluation of intravesical oxybutynin: bolus and continuous delivery. J Urol 2001, 165:252–253.

    Google Scholar 

  21. Pietzko A, Dimpfel W, Schwantes U, Topfmeier P: Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994, 47:337–343.

    Article  PubMed  CAS  Google Scholar 

  22. Hofner K, Oelke M, Machtens S, Grunewald V: Trospium chloride: an effective drug in the treatment of overactive bladder and detrusor hyper-reflexia. World J Urol 2001, 19:336–343. This is a well-written summary of the up-to-date clinical studies on trospium.

    Article  PubMed  CAS  Google Scholar 

  23. Hawthorn MH, Chapple CR, Cock M, Chess-Williams R: Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol 2000, 129:416–419.

    Article  PubMed  CAS  Google Scholar 

  24. Cardozo L, Chapple CR, Toozs-Hobson P, et al.: Efficacy of trospium chloride in patient with detrusor instability: a placebo-controlled, randomized, double blind, multicentre clinical trial. BJU Int 2000, 85:659–664.

    Article  PubMed  CAS  Google Scholar 

  25. Stohrer M, Bauer P, Giannetti BM, et al.: Effect of trospium chloride on urodynamic parameters n patients with detrusor hyper-reflexia due to spinal cord injuries: a multicentre, placebo-controlled, double-blind trial. Urol Int 1991, 47:138–143.

    Article  PubMed  CAS  Google Scholar 

  26. Alloussi S, Laval KU, Eckert R, et al.: Trospium chloride in a patient with motor urge syndrome (detrusor instability): a double-blind, randomized, multicentre, placebo-controlled study. J Clin Res Drug Dev 1998, 1:439–451.

    Google Scholar 

  27. Hofner K, Halaska M, Primus G, et al.: Tolerability and efficacy of trospium chloride in a long-term treatment (52 weeks) in patients with urge syndrome: a double-blind, controlled, multicentre clinical trial. Neurourol Urodyn 2000, 19:487–488.

    Google Scholar 

  28. Donnellan CA, Fook L, McDonald P, Playfer JR: Oxybutynin and cognitive dysfunction. BMJ 1997, 315:1363–1364.

    PubMed  CAS  Google Scholar 

  29. Katz IR, Sands LP, Bilker W, et al.: Identification of medications that can cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998, 46:8–13.

    PubMed  CAS  Google Scholar 

  30. Newgreen DT, Anderson DW, Carter AJ, et al.: Darifenacin: a novel bladder-selective agent for the treatment of urge incontinence. Neurourol Urodyn 1995, 14:555–557.

    Google Scholar 

  31. Braverman AS, Ruggieri MR, Pontari MA: The M2 muscarinic receptor subtype mediates cholinergic bladder contractions in patients with neurogenic bladder dysfunction. J Urol 2001, 165:36.

    Google Scholar 

  32. Braverman AS, Tallarida RJ, Ruggieri MR: Interaction between muscarinic receptor subtype signal transduction pathways mediating bladder contraction. Am J Physiol Regul Integr Comp Physiol 2002, 283:1–6.

    Google Scholar 

  33. Rosario DJ, Cutinha PE, Chapple CR: The effects of single-dose darifenacin on cystometric parameters and salivary flow in patients with urge incontinence secondary to detrusor instability. Eur Urol 1996, 30:240.

    Google Scholar 

  34. Chapple CR, Arano P, Bosch JH, et al.: YM 905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo and tolterodine controlled phase II dose finding study. Neurourol Urodyn 2002, 21:381–382.

    Google Scholar 

  35. Norton P, Zinner N, Yalcin I, et al.: Duloxetine versus placebo in the treatment of stress urinary incontinence. Neurourol Urodyn 2001, 20:532–534.

    Google Scholar 

  36. MacMahon SB, Spillane K: Brain stem influences on the parasympathetic supply to the urinary bladder of the cat. Brain Res 1982, 234:237–249.

    Article  Google Scholar 

  37. Espey MJ, Downie JW: Serotonergic modulation of cat bladder function before and after spinal transection. Eur J Pharmacol 1995, 287:173–177.

    Article  PubMed  CAS  Google Scholar 

  38. Thor KB, Katofiasc MA: Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 1995, 274:1014–1024.

    PubMed  CAS  Google Scholar 

  39. Zinner N, Dmochowski R, Miklos J, et al.: Duloxetine versus placebo in the treatment of stress urinary incontinence (SUI). Neurourol Urodyn 2002, 21:383–384.

    Google Scholar 

  40. Schurch B, Stohrer M, Kramer G, et al.: Botulinum-A toxin for treating detrusor hyper-reflexia in spinal cord injured patients: A new alternative to anticholinergic drug? Preliminary report. J Urol 2000, 164:692–697.

    Article  PubMed  CAS  Google Scholar 

  41. Yamaguchi O: _3 Adrenoreceptors in human detrusor muscle. Urology 2002, 59:25–29.

    Article  PubMed  Google Scholar 

  42. Takeda M, Obara K, Mizusawa T, et al.: Evidence for _3 adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 1999, 288:1367–1373.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Hospital of the University of Pennsylvania, 3400 Spruce Street, 19104, Philadelphia, PA, USA

    Eric S. Rovner MD

Authors
  1. Eric S. Rovner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan J. Wein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rovner, E.S., Wein, A.J. Update on overactive bladder: Pharmacologic approaches on the horizon. Curr Urol Rep 4, 385–390 (2003). https://doi.org/10.1007/s11934-003-0013-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-003-0013-3

Keywords

Search

Navigation